162 related articles for article (PubMed ID: 12827305)
1. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype.
Lu X; Kallinteris NL; Li J; Wu S; Li Y; Jiang Z; Hillman GG; Gulfo JV; Humphreys RE; Xu M
Cancer Immunol Immunother; 2003 Oct; 52(10):592-8. PubMed ID: 12827305
[TBL] [Abstract][Full Text] [Related]
2. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.
Hillman GG; Kallinteris NL; Li J; Wang Y; Lu X; Li Y; Wu S; Wright JL; Slos P; Gulfo JV; Humphreys RE; Xu M
Gene Ther; 2003 Aug; 10(17):1512-8. PubMed ID: 12900767
[TBL] [Abstract][Full Text] [Related]
3. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG
Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259
[TBL] [Abstract][Full Text] [Related]
4. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
5. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma.
Hillman GG; Xu M; Wang Y; Wright JL; Lu X; Kallinteris NL; Tekyi-Mensah S; Thompson TC; Mitchell MS; Forman JD
Hum Gene Ther; 2003 May; 14(8):763-75. PubMed ID: 12804139
[TBL] [Abstract][Full Text] [Related]
6. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
7. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
Qiu G; Goodchild J; Humphreys RE; Xu M
Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
10. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
12. Delayed allograft rejection by the suppression of class II transactivator.
Kim TW; Choi YM; Seo JN; Kim JH; Suh YH; Chung DH; Jung KC; Oh KI
Exp Mol Med; 2006 Jun; 38(3):210-6. PubMed ID: 16819279
[TBL] [Abstract][Full Text] [Related]
13. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.
Lee YS; Kim SH; Cho JA; Kim CW
Exp Mol Med; 2011 May; 43(5):281-90. PubMed ID: 21464590
[TBL] [Abstract][Full Text] [Related]
14. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
15. Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination.
Kerkmann-Tucek A; Banat GA; Cochlovius B; Zöller M
Int J Cancer; 1998 Jul; 77(1):114-22. PubMed ID: 9639402
[TBL] [Abstract][Full Text] [Related]
16. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
17. Highly efficient peptide binding and T cell activation by MHC class II molecules of CIITA-transfected cells.
Martinez-Soria E; Siegrist CA; Mach B
Int Immunol; 1996 Apr; 8(4):543-9. PubMed ID: 8671641
[TBL] [Abstract][Full Text] [Related]
18. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
19. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
[TBL] [Abstract][Full Text] [Related]
20. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]